The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Open accessAbstract
BACKGROUND: The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown. METHODS: Patients with chronic hepatitis B who had histologically confirmed cirrhosis or advanced fibrosis were randomly assigned in a 2:1 ratio to receive lamivudine (100 mg per day) or placebo for a maximum of five years. Of 651 patients, 436 were assigned to receive lamivudine and 215 to receive placebo. The primary end point was time to disease progression, defined by hepatic decompensation, hepatocellular carcinoma, spontaneous bacterial peritonitis, bleeding gastroesophageal varices, or death related to liver disease. An independent data and safety monitoring board monitored the progress of the study and performed interim analyses of the data. RESULTS: We randomly assigned 651 patients (98 percent Asian and 85 percent male) to receive lamivudine or placebo. The study was terminated after a median duration of treatment of 32.4 months (range, 0 to 42) owing to a significant difference between treatment groups in the number of end points reached. End points were reached by 7.8 percent of the patients receiving lamivudine and 17.7 percent of those receiving placebo (hazard ratio for disease progression, 0.45; P=0.001). The Child-Pugh score increased in 3.4 percent of the patients receiving lamivudine and 8.8 percent of those receiving placebo (hazard ratio, 0.45; P=0.02), whereas hepatocellular carcinoma occurred in 3.9 percent of those in the lamivudine group and 7.4 percent of those in the placebo group (hazard ratio, 0.49; P=0.047). Genotypic resistance YMDD mutations developed in 49 percent of the patients treated with lamivudine, and the Child-Pugh score was more likely to increase in patients with these mutations than in the other patients treated with lamivudine (7 percent vs. <1 percent). Overall, 12 percent of the patients in the lamivudine group and 18 percent of the patients in the placebo group reported serious adverse events. CONCLUSIONS: Continuous treatment with lamivudine delays clinical progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis by significantly reducing the incidence of hepatic decompensation and the risk of hepatocellular carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Self-citationHepatitis B virus.The major etiology of hepatocellular carcinoma
Beasley, R. P. (1988) · Cancer · doi:10.1002/1097-0142(19880515)61:10<1942::aid-cncr2820611003>3.0.co;2-j · Cited by 1,280
Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y., Hsiao, C. K., Chen, P.-J., Chen, D.-S., & Chen, C.-J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013215 · Cited by 1,222
Self-citationLAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
Histological outcome during long-term lamivudine therapy
Dienstag, J. L., Goldin, R. D., Heathcote, E. J., Hann, H. W. L., Woessner, M., Stephenson, S. L., Gardner, S., Gray, D. F., & Schiff, E. R. (2003) · Gastroenterology · doi:10.1053/gast.2003.50013 · Cited by 726
Self-citationTables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
Lok, A. S. F., & McMahon, B. J. (2001) · Hepatology · doi:10.1053/jhep.2001.29401 · Cited by 709
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
Hsu, Y.-S., Chien, R.-N., Yeh, C.-T., Sheen, I.-S., Chiou, H.-Y., Chu, C.-M., & Liaw, Y.-F. (2002) · Hepatology · doi:10.1053/jhep.2002.33638 · Cited by 705
Self-citationLai, C., Dienstag, J., Schiff, E., Leung, N. W. Y., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R., & Condreay, L. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 634
The Design and Analysis of Sequential Clinical Trials.
Harrington, D., & Whitehead, J. (1985) · Journal of the American Statistical Association · doi:10.2307/2288093 · Cited by 634
Leung, N. W. Y., Lai, C.-L., Chang, T.-T., Guan, R., Lee, C.-M., Ng, K.-Y., Lim, S.-G., Wu, P.-C., Dent, J. C., Edmundson, S., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.25084 · Cited by 626
Self-citationThe development of cirrhosis in patients with chronic type B hepatitis: A prospective study
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., & Chen, T.-J. (1988) · Hepatology · doi:10.1002/hep.1840080310 · Cited by 612
Self-citationThe Design and Analysis of Sequential Clinical Trials.
Whitehead, J. (1997) · Biometrics · doi:10.2307/2533535 · Cited by 516
Lin, S.-M., Sheen, I.-S., Chien, R.-N., Chu, C.-M., & Liaw, Y.-F. (1999) · Hepatology · doi:10.1002/hep.510290312 · Cited by 444
Self-citationProspective Analysis of Risk Factors for Hepatocellular Carcinoma in Patients With Liver Cirrhosis
Velázquez, R. F., Rodríguez, M., Navascués, C. A., Linares, A., Pérez, R., Sotorríos, N. G., Martínez, I., & Rodrigo, L. (2003) · Hepatology · doi:10.1053/jhep.2003.50093 · Cited by 440
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
De Jongh, F. E., Janssen, H. L. A., De Man, R. A., Hop, W. C. J., Schalm, S. W., & Van Blankenstein, M. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91188-a · Cited by 418
Realdi, G., The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP), Fattovich, G., Hadziyannis, S., Schalm, S. W., Almasio, P., Sanchez-Tapias, J., Christensen, E., Giustina, G., & Noventa, F. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80115-0 · Cited by 301
Survival in Chronic Hepatitis B: An Analysis of 379 Patients
WEISSBERG, J. I., ANDRES, L. L., SMITH, C. I., WEICK, S., NICHOLS, J. E., GARCIA, G., ROBINSON, W. S., MERIGAN, T. C., & GREGORY, P. B. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-5-613 · Cited by 260
Yuen, M.-F., Hui, C.-K., Cheng, C.-C., Wu, C.-H., Lai, Y.-P., & Lai, C.-L. (2001) · Hepatology · doi:10.1053/jhep.2001.25273 · Cited by 232
Lampertico, P., Del Ninno, E., Viganò, M., Romeo, R., Donato, M. F., Sablon, E., Morabito, A., & Colombo, M. (2003) · Hepatology · doi:10.1053/jhep.2003.50148 · Cited by 215
The Design and Analysis of Sequential Clinical Trials (2nd ed.).
Lachenbruch, P. A., & Whitehead, J. (1993) · Journal of the American Statistical Association · doi:10.2307/2290372 · Cited by 108
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*
Liaw, Y., Leung, N. W. Y., Guan, R., Lau, G. K. K., & Merican, I. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03037.x · Cited by 100
Self-citationManagement of Patients with Decompensated HBV Cirrhosis
Fontana, R. J. (2003) · Seminars in Liver Disease · doi:10.1055/s-2003-37591 · Cited by 54
Hui, J. M., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E. B., & Farrell, G. C. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05621.x · Cited by 19
Self-citationChronic Hepatitis B and Hepatocarcinogenesis: Does Prevention of “Collateral Damage” Bring the Cure?
Manigold, T., & Rehermann, B. (2003) · Hepatology · doi:10.1002/hep.510370328 · Cited by 9
Cited by
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Metadata
- Authors
- Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., Dixon, J. S., Gray, D. F., & Sabbat, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-07
- Volume
- 351
- Issue
- 15
- Pages
- 1521-1531
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2004054613
- Cited by
- 2,266
- References
- 31
- FWCI
- 76.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.